Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

NCT05130866 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
25
Enrollment
INDUSTRY
Sponsor class

Stopped Study was terminated due to sponsor decision. This decision was not related to safety concerns with REC-2282.

Conditions

Interventions

Sponsor

Recursion Pharmaceuticals Inc.